OpenAlex
PricingAboutJobs
Log inGet started
Work

Neoadjuvant treatment with trastuzumab and pertuzumab plus palbociclib and fulvestrant in HER2-positive, ER-positive breast cancer (NA-PHER2): an exploratory, open-label, phase 2 study

HTML

Year: 2018
Type: article
Study design: Clinical Trial
Source: The Lancet Oncology
DOI: 10.1016/s1470-2045(18)30001-9
Authors: Luca Gianni, Giancarlo Bisagni, Marco Colleoni, Lucia Del Mastro, Claudio Zamagni, Mauro Mansutti, Milvia Zambetti, Antonio Frassoldati, Raffaella De Fato, Pinuccia Valagussa, Giuseppe Viale
Institutions: IRCCS Ospedale San Raffaele, European Institute of Oncology, Ospedale Policlinico San Martino, IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola, Azienda sanitaria universitaria Friuli Centrale, Arcispedale Sant'Anna, Fondazione Michelangelo
Language: English

Topic: Advanced Breast Cancer Therapies
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Keywords: HER2-positive breast cancer, estrogen receptor-positive breast cancer, neoadjuvant therapy, trastuzumab, pertuzumab, palbociclib, fulvestrant, Ki-67, apoptosis, pathological complete response, combination targeted therapy, treatment safety, adverse events, drug discontinuation
SDG: Good health and well-being

Open Access status: closed

Funders: Pfizer, Roche, Roche Italia, European Society for Medical Oncology
OpenAlex ID: W2782896696
FWCI: 8.809
Cites: 28
Cited by: 184
Related to: 10
OpenAlex
Nonprofit
Open DataOpen Data
Open Source
Product
Search
Compare
Pricing
Repositories
Unpaywall
Unsub
Developers
API docs
Data snapshot
Status
Source code
Organization
About
Team
Testimonials
Brand
Jobs
Community
Help center
Contact
Events
Blog
Mailing list
Subscribe
Supporters
Legal
Privacy
Accessibility
Terms
Security